358 related articles for article (PubMed ID: 27061020)
1. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
Panchmatia HR; Clements KM; Hulbert E; Eriksson M; Wittrup-Jensen K; Nilsson J; Weinstein MC
Acta Ophthalmol; 2016 Aug; 94(5):441-8. PubMed ID: 27061020
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis.
Hernandez L; Lanitis T; Cele C; Toro-Diaz H; Gibson A; Kuznik A
J Manag Care Spec Pharm; 2018 Jul; 24(7):608-616. PubMed ID: 29952707
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
Vottonen P; Kankaanpää E
Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048
[TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan.
Yanagi Y; Fukuda A; Barzey V; Adachi K
J Med Econ; 2017 Feb; 20(2):204-212. PubMed ID: 27701921
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison.
Ohji M; Lanzetta P; Korobelnik JF; Wojciechowski P; Taieb V; Deschaseaux C; Janer D; Tuckmantel C
Adv Ther; 2020 May; 37(5):2184-2198. PubMed ID: 32222903
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab.
Elwes F; Borooah S; Aspinall P; Sim PY; Loo CY; Armbrecht AM; Dhillon B; Cackett P
BMC Ophthalmol; 2018 Jan; 18(1):20. PubMed ID: 29378528
[TBL] [Abstract][Full Text] [Related]
8. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
Brown GC; Brown MM; Rapuano S; Boyer D
Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
[TBL] [Abstract][Full Text] [Related]
9. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration.
Chen R; Wu B
Ann Transl Med; 2020 Aug; 8(15):939. PubMed ID: 32953739
[TBL] [Abstract][Full Text] [Related]
11. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
[TBL] [Abstract][Full Text] [Related]
12. Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom.
Claxton L; Hodgson R; Taylor M; Malcolm B; Pulikottil Jacob R
Pharmacoeconomics; 2017 Feb; 35(2):237-248. PubMed ID: 27787744
[TBL] [Abstract][Full Text] [Related]
13. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.
Elshout M; van der Reis MI; Webers CA; Schouten JS
Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1911-20. PubMed ID: 24777708
[TBL] [Abstract][Full Text] [Related]
14. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
[No Abstract] [Full Text] [Related]
15. Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW.
Weber M; Dominguez M; Coscas F; Faure C; Baillif S; Kodjikian L; Cohen SY
BMC Ophthalmol; 2020 May; 20(1):206. PubMed ID: 32450838
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
Stein JD; Newman-Casey PA; Mrinalini T; Lee PP; Hutton DW
Ophthalmology; 2014 Apr; 121(4):936-45. PubMed ID: 24405740
[TBL] [Abstract][Full Text] [Related]
17. UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice.
Lee AY; Lee CS; Egan CA; Bailey C; Johnston RL; Natha S; Hamilton R; Khan R; Al-Husainy S; Brand C; Akerele T; Mckibbin M; Downey L; Tufail A
Br J Ophthalmol; 2017 Dec; 101(12):1683-1688. PubMed ID: 28478396
[TBL] [Abstract][Full Text] [Related]
18. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
Lanzetta P; Cruess AF; Cohen SY; Slakter JS; Katz T; Sowade O; Zeitz O; Ahlers C; Mitchell P
Acta Ophthalmol; 2018 Dec; 96(8):e911-e918. PubMed ID: 29659183
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept in exudative age related macular degeneration refractory to ranibizumab.
Ruiz Ramos J; Pascual-Camps I; Cuéllar-Monreal MJ; Dolz-Marco R; Fenoll MA; Font-Noguera I; Poveda-Andrés JL; Gallego-Pinazo R
Arch Soc Esp Oftalmol; 2015 Dec; 90(12):566-71. PubMed ID: 26515015
[TBL] [Abstract][Full Text] [Related]
20. The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK.
Ghosh W; Wickstead R; Claxton L; Kusel J; Taylor M; Fleetwood K; Pulikottil-Jacob R
Adv Ther; 2016 Sep; 33(9):1660-76. PubMed ID: 27457470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
